| 2 | 1/1 | 返回列表 |
| 查看: 559 | 回復: 1 | |||
| 本帖產(chǎn)生 1 個 翻譯EPI ,點擊這里進行查看 | |||
霜葉金蟲 (小有名氣)
|
[求助]
請幫忙翻譯一段摘要,非常感謝
|
||
|
PURPOSE: Our goal was to compare the analgesic efficacy and safety of single doses of intravenous parecoxib sodium, a prodrug of the novel cyclooxygenase (COX)-2-selective inhibitor valdecoxib, with intravenous ketorolac and placebo in postoperative oral surgery patients. PATIENTS AND METHODS: Eligible patients experiencing moderate to severe pain within 6 hours of surgery to extract 2 or more impacted third molars were randomized to receive a single dose of parecoxib sodium 1, 2, 5, 10, 20, 50, or 100 mg; ketorolac 30 mg; or placebo. Analgesic efficacy was assessed over a 24-hour treatment period or until rescue analgesia was required. RESULTS: Parecoxib sodium doses (particularly 50 and 100 mg) had a rapid onset of analgesia (within 11 minutes). The analgesic efficacy of parecoxib sodium 20 to 100 mg was similar to that of ketorolac 30 mg. Parecoxib sodium doses below 20 mg had suboptimal analgesic activity compared with placebo and ketorolac. A plateau of efficacy was observed at the parecoxib sodium 50-mg dose. Parecoxib sodium 50 and 100 mg had a significantly longer duration of analgesia than ketorolac 30 mg. All doses of parecoxib sodium were well tolerated. CONCLUSIONS: Parecoxib sodium, a novel parenteral prodrug of the COX-2-selective inhibitor valdecoxib, is as effective and longer acting at 50- and 100-mg intravenous doses than a standard dose of ketorolac 30 mg intravenously. Parecoxib sodium appears to be safe and well tolerated and, therefore, merits further evaluation in other models of postsurgical pain. |
木蟲 (正式寫手)
|
目的: 我們的目標是比較單劑量靜脈給藥帕瑞昔布鈉--新型環(huán)氧合酶(COX)-2選擇性抑制劑伐地考昔的前體藥物,與靜脈給藥酮咯酸和安慰劑對口腔手術患者術后鎮(zhèn)痛的有效性和安全性。 患者和方法: 符合條件的患者---拔除2顆或更多顆智齒手術后6小時內(nèi)有中度至重度疼痛的患者,被隨機分配接受單劑量帕瑞昔布鈉1、2、5、10、20、50或100毫克,酮咯酸30毫克或安慰劑。在給藥后超過24小時期間或直到需要止痛前,對鎮(zhèn)痛效果進行評價。 帕瑞昔布鈉劑量(特別是50和100毫克)具有速效鎮(zhèn)痛作用(11分鐘內(nèi))。帕瑞昔布鈉20-100毫克的鎮(zhèn)痛效果與酮咯酸30毫克的鎮(zhèn)痛效果類似。低于20毫克的帕瑞昔布鈉劑量的鎮(zhèn)痛活性,不及安慰劑和酮咯酸。帕瑞昔布鈉50毫克劑量觀察到療效達到穩(wěn)定水平。帕瑞昔布鈉50和100毫克有與酮咯酸30毫克相比,鎮(zhèn)痛作用持續(xù)時間更長。帕瑞昔布鈉的所有劑量均具有良好的耐受性。 結(jié)論: 帕瑞昔布鈉,一種新型COX-2選擇性抑制劑伐地考昔的靜脈用前體藥物,以50 - 100毫克劑量靜脈給藥,與標準劑量酮咯酸30毫克靜脈給藥相比,具有良好且持續(xù)時間較長的鎮(zhèn)痛作用。帕瑞昔布鈉安全且耐受性良好,因此,值得在術后疼痛模型中進一步研究。 |

| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 0703 化學 求調(diào)劑,一志愿山東大學 342 分 +4 | Shern—- 2026-03-28 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 315求調(diào)劑 +4 | akie... 2026-03-28 | 5/250 |
|
|
[考研] 332求調(diào)劑 +4 | @MZB382400 2026-03-28 | 4/200 |
|
|
[考研] 一志愿華理,數(shù)一英一285求A區(qū)調(diào)劑 +8 | AZMK 2026-03-25 | 12/600 |
|
|
[考研] 一志愿北京工業(yè)大學,324分求調(diào)劑 +4 | 零八# 2026-03-28 | 4/200 |
|
|
[考研] 295求調(diào)劑 +5 | 1428151015 2026-03-27 | 6/300 |
|
|
[考研] 283求調(diào)劑(080500) +4 | A child 2026-03-27 | 4/200 |
|
|
[考研] 0703化學338求調(diào)劑! +6 | Zuhui0306 2026-03-26 | 7/350 |
|
|
[考研] 341求調(diào)劑 +7 | 青檸檬1 2026-03-26 | 7/350 |
|
|
[考研] 總分322求生物學/生化與分子/生物信息學相關調(diào)劑 +5 | 星沉uu 2026-03-26 | 6/300 |
|
|
[考研] 281求調(diào)劑 +6 | Koxui 2026-03-24 | 7/350 |
|
|
[考研] 一志愿 南京郵電大學 288分 材料考研 求調(diào)劑 +3 | jl0720 2026-03-26 | 3/150 |
|
|
[考研] 一志愿南航 335分 | 0856材料化工 | GPA 4.07 | 有科研經(jīng)歷 +6 | cccchenso 2026-03-23 | 6/300 |
|
|
[考研] 334分 一志愿武理-080500 材料求調(diào)劑 +4 | 李李不服輸 2026-03-25 | 4/200 |
|
|
[考研] 一志愿中南大學化學學碩0703總分337求調(diào)劑 +7 | niko- 2026-03-22 | 7/350 |
|
|
[考研] 材料專碩 335 分求調(diào)劑 +4 | 拒絕冷暴力 2026-03-25 | 4/200 |
|
|
[考研] 求調(diào)劑 +3 | 李李不服輸 2026-03-25 | 3/150 |
|
|
[考研] 340求調(diào)劑 +5 | 話梅糖111 2026-03-24 | 5/250 |
|
|
[考研] 材料專碩找調(diào)劑 +5 | 哈哈哈吼吼吼哈 2026-03-23 | 5/250 |
|
|
[考研] 材料專碩331求調(diào)劑 +4 | 鮮當牛 2026-03-24 | 4/200 |
|